KalVista Pharmaceuticals (KALV) Tops Q3 EPS by 23c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.75), $0.23 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers
• Softbank stock target raised at Citi on profit growth
• Merck (MRK) PT Raised to $155 at Scotiabank